IVM with Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer for Polycystic Ovary Syndrome
This study is looking at a new way to help women with Polycystic Ovary Syndrome (PCOS) get pregnant using in vitro maturation (IVM). IVM involves collecting immature eggs and letting them mature in the lab before fertilization. This study uses oral medications like letrozole and very low doses of FSH (follicle-stimulating hormone) to prepare the ovaries, and a special needle (Steiner-Tan) for egg retrieval. After fertilization, embryos are frozen and transferred in a later cycle. We want to see how many patients become pregnant after 12 weeks and how many have an ongoing pregnancy after 10 months. You may be able to join if you are a woman between 18 and 38 years old, have a specific pattern of follicles in your ovaries (PCO pattern), and an AMH (Anti-Müllerian Hormone) level above 3.5. We cannot tell you if the study is currently enrolling.
- Study design
- This is an interventional study with a planned enrollment of 300 participants. All participants will receive the IVM treatment.
- What's involved
- You will take oral contraceptives, then oral letrozole and low-dose FSH. You will have an HCG injection, followed by egg retrieval approximately 38 hours later. Embryos will be frozen and transferred in a separate cycle.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your pregnancy status will be checked at 12 weeks after embryo transfer and again at 10 months after embryo transfer.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Bruce I Rose, MD, PhD · PRINCIPAL_INVESTIGATOR · Brown Fertility
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Percentage of treated patients having a clinical pregnancy12 weeks post transfer
ultrasound evidence of pregnancy in uterus or tissue evidence of pregnancy
- Percentage of treated patients having an ongoing pregnancy10 months post transfer
pregnancy with cardiac activity (by history or observations) after 12 weeks